1. Home
  2. GEVO vs ORKA Comparison

GEVO vs ORKA Comparison

Compare GEVO & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GEVO
  • ORKA
  • Stock Information
  • Founded
  • GEVO 2005
  • ORKA 2004
  • Country
  • GEVO United States
  • ORKA United States
  • Employees
  • GEVO N/A
  • ORKA N/A
  • Industry
  • GEVO Major Chemicals
  • ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • GEVO Industrials
  • ORKA Health Care
  • Exchange
  • GEVO Nasdaq
  • ORKA Nasdaq
  • Market Cap
  • GEVO 354.6M
  • ORKA 354.2M
  • IPO Year
  • GEVO 2011
  • ORKA N/A
  • Fundamental
  • Price
  • GEVO $1.47
  • ORKA $14.25
  • Analyst Decision
  • GEVO Buy
  • ORKA Strong Buy
  • Analyst Count
  • GEVO 2
  • ORKA 8
  • Target Price
  • GEVO $7.58
  • ORKA $39.71
  • AVG Volume (30 Days)
  • GEVO 4.9M
  • ORKA 365.5K
  • Earning Date
  • GEVO 08-11-2025
  • ORKA 08-15-2025
  • Dividend Yield
  • GEVO N/A
  • ORKA N/A
  • EPS Growth
  • GEVO N/A
  • ORKA N/A
  • EPS
  • GEVO N/A
  • ORKA N/A
  • Revenue
  • GEVO $42,034,000.00
  • ORKA N/A
  • Revenue This Year
  • GEVO $1,022.79
  • ORKA N/A
  • Revenue Next Year
  • GEVO $12.26
  • ORKA N/A
  • P/E Ratio
  • GEVO N/A
  • ORKA N/A
  • Revenue Growth
  • GEVO 145.38
  • ORKA N/A
  • 52 Week Low
  • GEVO $0.48
  • ORKA $5.49
  • 52 Week High
  • GEVO $3.39
  • ORKA $52.32
  • Technical
  • Relative Strength Index (RSI)
  • GEVO 52.84
  • ORKA N/A
  • Support Level
  • GEVO $1.43
  • ORKA N/A
  • Resistance Level
  • GEVO $1.58
  • ORKA N/A
  • Average True Range (ATR)
  • GEVO 0.09
  • ORKA 0.00
  • MACD
  • GEVO -0.01
  • ORKA 0.00
  • Stochastic Oscillator
  • GEVO 36.36
  • ORKA 0.00

About GEVO Gevo Inc.

Gevo Inc is a renewable chemicals and biofuels company engaged in the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks. The operating segments are the Gevo segment, GevoFuels segment, and the GevoRNG segment. By its segments, it is involved in research and development activities related to the future production of SAF, commercial opportunities for other renewable hydrocarbon products and isobutanol, including the development of its biocatalysts, and the produces-pipeline quality methane gas captured from dairy cow manure. The company derives maximum revenue from the GevoRNG segment.

About ORKA Oruka Therapeutics Inc. Common Stock

Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.

Share on Social Networks: